HCW Biologics Inc. financial data

Symbol
HCWB on Nasdaq
Industry
Pharmaceutical Preparations
Location
2929 N Commerce Pkwy, Miramar, FL
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 56.8 % -92.8%
Debt-to-equity 205 % +624%
Return On Equity -386 % -628%
Return On Assets -126 % -206%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8M shares +5.28%
Entity Public Float 42.8M USD -2.95%
Common Stock, Value, Issued 3.78K USD +5.26%
Weighted Average Number of Shares Outstanding, Basic 37.8M shares +5.33%
Weighted Average Number of Shares Outstanding, Diluted 37.8M shares +5.33%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 2.7M USD -11.5%
Research and Development Expense 7.96M USD -15.8%
General and Administrative Expense 16.2M USD +71.8%
Operating Income (Loss) -38.5M USD -96.7%
Nonoperating Income (Expense) -1.3M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -38.4M USD -105%
Earnings Per Share, Basic -1.04 USD/shares -100%
Earnings Per Share, Diluted -1.04 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.16M USD -84.4%
Other Assets, Current 165K USD -49.7%
Assets, Current 2.39M USD -88%
Property, Plant and Equipment, Net 22.8M USD +80.7%
Operating Lease, Right-of-Use Asset 28.1K USD -85.3%
Other Assets, Noncurrent 28.5K USD -86.5%
Assets 26.8M USD -32.1%
Accounts Payable, Current 16.9M USD +698%
Liabilities, Current 23.2M USD +412%
Deferred Income Tax Liabilities, Net 147K USD
Operating Lease, Liability, Noncurrent 7.48K USD -94.6%
Liabilities 33.1M USD +204%
Retained Earnings (Accumulated Deficit) -93.3M USD -69.9%
Stockholders' Equity Attributable to Parent -6.3M USD -122%
Liabilities and Equity 26.8M USD -32.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.6M USD +0.94%
Net Cash Provided by (Used in) Financing Activities 4.22M USD +122%
Net Cash Provided by (Used in) Investing Activities -130K USD +56.8%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 37.8M shares +5.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 489K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.16M USD -84.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.4M USD +58.5%
Cash and Cash Equivalents, Period Increase (Decrease) 6.39M USD
Deferred Tax Assets, Gross 18.5M USD +59.8%
Operating Lease, Liability 153K USD -50%
Payments to Acquire Property, Plant, and Equipment 130K USD -56.8%
Property, Plant and Equipment, Gross 23.5M USD +80.1%
Operating Lease, Liability, Current 28.1K USD -84.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.7K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 28.8K USD -31.9%
Additional Paid in Capital 87M USD +4.17%
Depreciation, Depletion and Amortization 244K USD -18.5%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 28.7K USD -83.3%
Operating Leases, Future Minimum Payments Due 28.7K USD -85.7%
Interest Expense 254K USD -19.6%